{
    "clinical_study": {
        "@rank": "89224", 
        "arm_group": {
            "arm_group_label": "Treatment", 
            "arm_group_type": "Experimental", 
            "description": "AXIOS Stent with Electrocautery Enhanced Delivery System"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to demonstrate the safety and effectiveness of the AXIOS Stent\n      with Electrocautery Enhanced Delivery System for endoscopic transenteric drainage of\n      pancreatic pseudocysts."
        }, 
        "brief_title": "AXIOS Stent With Electrocautery Enhanced Delivery System", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Pancreatic Pseudocyst(s)", 
        "condition_browse": {
            "mesh_term": "Pancreatic Pseudocyst"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Age between 18 and 75 years old, male or female\n\n          2. Eligible for endoscopic intervention\n\n          3. Acceptable candidate for endoscopic transluminal pancreatic pseudocyst drainage\n\n          4. Symptomatic pancreatic pseudocyst having the following characteristics:\n\n               -  Greater or equal to 6 cm in diameter (based upon the maximum cross-sectional\n                  area in the CT scan or transabdominal ultrasound).\n\n               -  Adherent to bowel wall, and\n\n               -  \u226570% fluid content\n\n          5. Patient understands the study requirements and the treatment procedures and provides\n             written Informed Consent.\n\n          6. Patient is willing to comply with all specified follow-up evaluations, including\n             willingness to undergo a pre/post CT imaging study.\n\n        Exclusion Criteria:\n\n          1. The fluid collection to be drained is an immature pseudocyst\n\n          2. The fluid collection to be drained is a cystic neoplasm\n\n          3. The fluid collection to be drained is a pseudoaneurysm\n\n          4. The fluid collection to be drained is a duplication cyst\n\n          5. The fluid collection to be drained is a non-inflammatory fluid collection\n\n          6. There is more than one pseudocyst requiring drainage\n\n          7. Abnormal coagulation:\n\n               -  INR > 1.5 and not correctable\n\n               -  presence of a bleeding disorder\n\n               -  platelets < 50,000/mm3\n\n          8. Altered anatomy that precludes the physician's ability to deliver the stent (decision\n             on a case by case basis).\n\n          9. Intervening gastric varices or vessels within a one centimeter radius of the needle\n             (visible using endoscopy or endoscopic ultrasound)\n\n         10. Any prior true anaphylactic reaction to contrast agents, nitinol (nickel   titanium),\n             silicone or any other materials contacting the patient.\n\n         11. Female of childbearing potential with a positive pregnancy test prior to the\n             procedure or intends to become pregnant during the study.\n\n         12. Currently participating in another investigational drug of device study that has not\n             completed the primary endpoint or that clinically interferes with the endpoints of\n             this study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "15", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 13, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02146352", 
            "org_study_id": "CP201303"
        }, 
        "intervention": {
            "arm_group_label": "Treatment", 
            "description": "Endoscopy with ultrasonography to implant AXIOS stent using electrocautery enhanced delivery system to allow drainage of pancreatic pseudocyst.  Removal of AXIOS stent after 30 or 60 days.", 
            "intervention_name": "AXIOS Stent with Electrocautery Enhanced Delivery System", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Pancreatic pseudocyst", 
        "lastchanged_date": "May 20, 2014", 
        "location": [
            {
                "contact": {
                    "email": "LINDSAY.HOSFORD@UCDENVER.EDU", 
                    "last_name": "Lindsay Hosford"
                }, 
                "facility": {
                    "address": {
                        "city": "Aurora", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80045"
                    }, 
                    "name": "University of Colorado Denver"
                }, 
                "investigator": {
                    "last_name": "Raj Shah, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "jchojn01@bgclinic.com", 
                    "last_name": "Jennifer Chojn"
                }, 
                "facility": {
                    "address": {
                        "city": "Jacksonville", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32256"
                    }, 
                    "name": "Borland-Groover Clinic"
                }, 
                "investigator": {
                    "last_name": "Jose Nieto, DO", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "sarah.l.cristofaro@emory.edu", 
                    "last_name": "Sarah Cristofaro"
                }, 
                "facility": {
                    "address": {
                        "city": "Atlanta", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30322"
                    }, 
                    "name": "Emory University"
                }, 
                "investigator": {
                    "last_name": "Field Willingham, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "akoons@medicine.bsd.uchicago.edu", 
                    "last_name": "Ann Koons"
                }, 
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60637"
                    }, 
                    "name": "University of Chicago Medical Center"
                }, 
                "investigator": {
                    "last_name": "Irving Waxman, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "THOLLAND@DOM.wustl.edu", 
                    "last_name": "Thomas Hollander"
                }, 
                "facility": {
                    "address": {
                        "city": "St. Louis", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63110"
                    }, 
                    "name": "Washington University in St. Louis"
                }, 
                "investigator": {
                    "last_name": "Steven Edmundowica, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "AXIOS Stent With Electrocautery Enhanced Delivery System", 
        "overall_official": {
            "affiliation": "Washington University School of Medicine", 
            "last_name": "Steven A Edmundowicz, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Freedom from major complications through the duration of the 1-week post-stent removal, defined as:\nAccess site-related bleeding requiring transfusion;\nAccess site-related infection requiring intravenous or intramuscular antibiotics and/or extended hospitalization;\nSurgery for access-site related perforation;\nStent migration/dislodgement into the pseudocyst or enteral lumen;\nTissue injury, defined as ulceration at site of stent implant as observed to persist through 1-week post-stent removal;\nSerious adverse event associated with the AXIOS stent and/or (index) implant procedure.", 
            "measure": "Safety/Adverse Event Outcome Measure", 
            "safety_issue": "Yes", 
            "time_frame": "Index procedure through 1-week post-stent removal"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02146352"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Stent Retention: The stent must remain in place for up to 60 days", 
                "measure": "Stent Retention Outcome Measure", 
                "safety_issue": "No", 
                "time_frame": "30 or 60 days post-procedure"
            }, 
            {
                "description": "Lumen Patency: The stent lumen must be patent at 30 days and/or 60 days of implantation.", 
                "measure": "Lumen Patency Outcome Measure", 
                "safety_issue": "No", 
                "time_frame": "30 and/or 60 days post-procedure"
            }, 
            {
                "description": "Technical success: Successful placement of the AXIOS stent using the Electrocautery Enhanced AXIOS Delivery System and successful removal of the AXIOS stent using a standard endoscopic snare or forceps.", 
                "measure": "Technical Success Outcome Measure", 
                "safety_issue": "No", 
                "time_frame": "Index Procedure and at 30 or 60 days post-procedure"
            }, 
            {
                "description": "Clinical success: At least a 50% decrease in pseudocyst size, based on radiographic analysis, at 30 days or 60 days.", 
                "measure": "Clinical Success Outcome Measure", 
                "safety_issue": "No", 
                "time_frame": "30 or 60 days post-procedure"
            }
        ], 
        "source": "Xlumena, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Xlumena, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}